Articles

Comparison of Therapies in Younger Patients with CLL
ASH 2019 – CLL
Results of the ECOG 1912 trial comparing chemoimmunotherapy with the oral BTK inhibitor ibrutinib plus rituximab in younger people with chronic lymphocytic leukemia (CLL). Read More ›
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions. Read More ›
New Immunotherapy Treatment Looks Promising in Relapsed/Refractory Multiple Myeloma
ASH 2019 – Multiple Myeloma: Wrap-Up
CAR T-cell therapy, a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells, has led to exciting results in other types of cancer…could it soon be used to treat multiple myeloma? Read More ›
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL
A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs. Read More ›
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
ASH 2019 – Post Wrap-Up, ASH 2019 – CLL
The results of this phase 3 study demonstrate a progression-free survival advantage for patients treated with acalabrutinib given alone or in combination with obinutuzumab versus those treated with obinutuzumab plus chlorambucil. Read More ›
Acalabrutinib-Based Combination Treatments for CLL
ASH 2019 – CLL
Results from ELEVATE-TN, a phase 3 study comparing the efficacy and safety of acalabrutinib given as a single agent; acalabrutinib combined with obinutuzumab; and obinutuzumab combined with chlorambucil in patients with untreated chronic lymphocytic leukemia (CLL). Read More ›
Combination Treatment for Follicular Lymphoma
ASH 2019 – CLL
Researchers tested the Pola-G-Len (polatuzumab vedotin, obinutuzumab, and lenalidomide) regimen to determine if it enhanced antitumor response in patients with relapsed or refractory follicular lymphoma. Read More ›
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL
Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features. Read More ›

Page 77 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy